Theracom, L.L.C.

Theracom, L.L.C., a Kentucky-based specialty pharmaceutical distributor and wholly-owned child entity of Cencora, Inc. (Amerisourcebergen), supplies high-cost biologic medications and specialty pharmaceuticals to federal healthcare systems exclusively as a prime contractor on full-and-open, non-set-aside basis. The company operates from headquarters in Shepherdsville, Kentucky with operational distribution facilities in Brooks, Kentucky and Northport, New York, specializing in emergency and routine procurement of specialty drugs including TAKHZYRO (lanadelumab) for hereditary angioedema treatment across Veterans Integrated Service Networks and military medical commands.

Theracom's federal footprint reflects narrow but concentrated customer exposure within the Department of Veterans Affairs healthcare system. The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 6 leads by award count with 42 orders (combined potential value $637 thousand), while the Department of the Army Medical Command anchors dollar volume with 10 awards worth $1.1 million in combined potential value. Veterans Integrated Service Network 2 places 14 awards valued at $625 thousand, and VISN 7 contributes 19 awards at $126 thousand. Beyond VA networks, the company serves the Department of the Navy Bureau of Medicine and Surgery (31 awards, $364 thousand) and the Indian Health Service (21 awards, $410 thousand). These five customers account for 29% of award count and 57% of combined potential value, reflecting heavy reliance on VA and military medical procurement channels.

All 440 awards in the source data are firm fixed-price purchase orders with typical completion cycles of two to thirty days, reflecting the urgent, routine replenishment nature of specialty pharmaceutical supply to federal medical facilities. Recent activity accelerated markedly—three awards in 2025 and eighteen in 2026 through late September—concentrating almost exclusively on TAKHZYRO formulations in varying dosages and delivery mechanisms (150 mg tablets, 150 mg/ml injections in 2 ml syringes). Individual order values cluster in the $37 thousand to $78 thousand range. Theracom operates without parent-vehicle reliance; only one Blanket Purchase Agreement (HHSI246201400158B under HHS Indian Health Service) appears across the award history, carrying five task orders valued at $91 thousand. The remainder flow as direct purchase orders from individual VA networks and military medical commands.

Theracom's classification in federal procurement aligns with primary NAICS 424210 (Drugs and Druggists' Sundries Merchant Wholesalers)—88 of 440 awards—and secondary NAICS codes for medical equipment and supplies distribution and pharmaceutical manufacturing. PSC codes show similar concentration: 202 awards under Medical And Surgical Instruments, Equipment, And Supplies; 180 awards under Drugs And Biologicals. The combined potential value of $5.5 million across 440 awards over two decades underscores the small-order, high-frequency nature of the business—essentially routine pharmaceutical replenishment at the federal medical network level rather than large systems contracts or IDIQs. Cencora's broader federal posture—including a $999.999 billion indefinite delivery contract with Defense Logistics Agency Troop Support Medical through December 2031—provides supply-chain infrastructure, but Theracom's distinct federal footprint remains transactional specialty drug distribution to VA and military healthcare.